Director - Access & Affordability Strategy and Execution

Job description

Why Patients Need You Pfizer’s U.S. migraine portfolio consists of two, complimentary, treatments – NURTEC ODT and ZAVZPRET. NURTEC ODT is the first and only FDA approved oral CGRP receptor antagonist that treats both acute and preventive migraine. NURTEC ODT has the opportunity to change the paradigm in migraine treatment and potentially establish a new standard of care. Pfizer’s product ZAVZPRET is the first intranasal calcitonin gene-related peptide (CGRP) monoclonal antibody indicated for the acute treatment of migraine attacks with or without aura. Following its launch in July 2023, ZAVZPRET has become the fastest growing acute non-oral product in the migraine space and continues to gain momentum. Migraine is a common, debilitating neurological disease affecting 40M people in the US. Surprisingly, less than half of the 19.5M people living with Migraine have been diagnosed, and fewer than half of those diagnosed are treated on Rx therapy. What You Will Achieve: The Director of Access & Affordability Strategy and Execution will lead the strategic development and optimization of access and affordability initiatives that advance franchise business objectives, drive meaningful pati...